CONTENTS

Introduction.................................................................................................................................... 422

Cryptosporidium............................................................................................................................

Epidemiology of Cryptosporidial Infection in Humans........................................................ 424

Cryptosporidial Clinical Manifestations............................................................................... 424

Cryptosporidiosis and Epithelial Cell Apoptosis.................................................................. 425

C. parvum-Associated Epithelial Cell Apoptosis in Patients................................................ 425

C. parvum-Associated Epithelial Cell Apoptosis In Vitro.................................................... 425

Mechanisms of C. parvum-Associated Epithelial Cell Apoptosis........................................ 425

Synergistic Effects of C. parvum Infection with HIV-I-Associated Soluble

Factors to Induce Epithelial Cell Apoptosis.......................................................................... 426

Diagnosis................................................................................................................................ 427

Therapy................................................................................................................................... 427

Epstein-Barr Virus......................................................................................................................... 427

EBV Clinical Manifestations................................................................................................. 428

Burkitt’s Lymphoma.............................................................................................................. 428

Lymphoproliferative Disorders..............................................................................................

EBV Proteins That Modulate Apoptosis................................................................................ 429

LMP1...................................................................................................................................... 429

CTAR1.................................................................................................................................... 430

CTAR2.................................................................................................................................... 430

EBNA1.................................................................................................................................... 430

EBNA2.................................................................................................................................... 431

EBNA3, EBNA4, EBNA5, EBNA6........................................................................................ 431

EBNA-LP................................................................................................................................ 431

EBER...................................................................................................................................... 432

Diagnosis and Therapy........................................................................................................... 432

Conclusions.................................................................................................................................... 432

References...................................................................................................................................... 432